|
|
Post by mssciguy on Aug 12, 2015 15:32:20 GMT -5
I'm in a corporate environment and only about 20% or less of our associates have a LinkedIn profile. so I call this the 80 / 20 rule. There are many more working on Afrezza than we will ever know. I have specified Afrezza on the Indeed job search site before, and not long ago (few weeks) it was populated every few days with new positions. Sometimes a few dozen. There is a flag "new" when new stuff comes up and it's probably more genuine than bogus because those items cost money to post in one way or another. If you want to be stealthy on LinkedIn you have to pay over $10k to get recruiter privileges or, you can do something cheaper and possibly far more accurate using the job search engines. It's amazing how much is out there... Everything looks positive with this launch. Sanofi did it safely, gathered data on efficacy and possibly superiority, now, to get the universal coverage and large enough volumes for the upper Tiers |
|
|
|
Post by joeypotsandpans on Aug 12, 2015 18:03:57 GMT -5
I know there are 90 in the Western region alone What is the extent of the Western region? That is all I got, didn't get into specifics of the states, etc., it was taken from a conversation regarding something else (ie., where this particular rep placed in their region) not so much about the number of reps per se. Sorry, can't go into much more than that. |
|
|
|
Post by longstocking on Aug 12, 2015 18:11:39 GMT -5
What is the extent of the Western region? That is all I got, didn't get into specifics of the states, etc., it was taken from a conversation regarding something else (ie., where this particular rep placed in their region) not so much about the number of reps per se. Sorry, can't go into much more than that. If "Western Region" means West of the Mississippi, that's still a lot of reps. Either way it's good to see SNY increasing staff to cover Afrezza. Appreciate the response. |
|
|
|
Post by jpg on Aug 12, 2015 18:13:03 GMT -5
Directly from Sny rep selling diabetes. Interesting. Not certain what to make of it though. On day 1 of the 'low key launch' I would have expected few reps detailing Afrezza and this to slowly grow with time. Is this what is happening? Also interesting (and highly encouraging for those who fear Afrezza being 'dumped') that Sanofi is sticking with Apidra insulin marketing regardless of the relatively low sales (and it's been a while!). Thank you. |
|
|
|
Post by saxcmann on Aug 12, 2015 18:54:01 GMT -5
Directly from Sny rep selling diabetes. Interesting. Not certain what to make of it though. On day 1 of the 'low key launch' I would have expected few reps detailing Afrezza and this to slowly grow with time. Is this what is happening? Also interesting (and highly encouraging for those who fear Afrezza being 'dumped') that Sanofi is sticking with Apidra insulin marketing regardless of the relatively low sales (and it's been a while!). Thank you. Agree jpg. I'm not sure what to make of it either. I wouldn't read too much into it. Just passing on what was said. My thoughts exactly on adding more reps as it grows. |
|
|
|
Post by kc on Aug 12, 2015 19:11:42 GMT -5
|
|
|
|
Post by xoxoxoxo on Aug 12, 2015 21:11:08 GMT -5
Putting this here from the monster.com search:
Sanofi
Director Payer Marketing Afrezza
Member of the U.S. Afrezza Brand team; responsible for the development and execution of the US Payer vision, strategy, and tactical plan as well as engaging with external experts, and evaluating marketing investments in support of the brand’s objectives in the Payer space.
Reports to: US Brand Lead, Afrezza
Direct reports: None
Key stakeholder relationships include:
Diabetes Brand/Launch Team leaders
US Sales Operations
Head, US Market Access
Lead, US Diabetes Market Development
Lead, US Diabetes Business Intelligence
VP, Head of US Diabetes Medical
Head, Diabetes Finance
Lead, US Diabetes Communications
Primary Responsibilities:
Key responsibilities will include:
· Develop comprehensive payer strategy and operational plans for these launch brands
· Work in close collaboration with US Market Access to build strategy and plans
· Develop and refine innovative pricing and contracting approaches to build sustainable relationships with strategic customers
· Accountable to manage the overall gross to net product contribution
· Manage the internal legal, regulatory, and medical review and approval of new materials to enable responsible Payer communications
· Manage budgets and closely monitor performance, ensuring cost effective delivery and positive ROI of all programs
· Integrate account, brand, category, and market knowledge to leverage insights and drive share growth
· Assist the business planning process by developing the payer section and providing insights and analytics to the overall plan
· Gather insight for customer segmenting and targeting for marketed products as well as competitive discount levels within the managed care market place
· Accountable for understanding government reimbursement including the impact of commercial contract pricing on government reimbursement in multiple government markets; collaborate with Government Pricing Team
Qualifications
Educational background and key experience:
Education:
• Bachelor's degree required
• MBA or other advanced degree is a plus
Experience:
• Minimum 5-7 years of marketing experience
• Market Access experience preferred
• Successful track record in the pharmaceutical/biotech or agency industry with 3+ years relevant experience
• Launch experience preferred
• Diabetes experience preferred
• Significant experience working with cross-functional groups made up of two or more of the following: Marketing, Sales, Research & Development, Health Outcomes, Medical Affairs, Business Development, Market Research, or Finance
Professional Skills:
• Experience utilizing economic data to support a business case
• Development of sustainable pricing and reimbursement strategies to optimize commercial value
• Experience in developing high impact marketing campaigns within a highly regulated environment
• Demonstrable track record of leading across the matrix to deliver results
• Detailed understanding of the US payer environment with an appreciation of the different evidence requirements by payer group
• Familarity with the componants of the Affordable Care Act and how these impact the payer customer
Key skills and competencies:
• Excellent organizational, interpersonal, and communication skills.
• Experience of leading a team, working with field sales forces and managing a budget
• Has significant knowledge of regulatory environment and has proven track record of managing tactical design, messaging and execution in industry
• Shows ability to use appropriate interpersonal styles and techniques and is able to modify one’s behavior to gain acceptance of ideas or plans
• Is able to focus and guide others in accomplishing work objectives
• Can build networks to obtain cooperation without relying on authority or supervision
• Demonstrated ability to work effectively with and influence a cross-functional, matrix group
|
|
|
|
Post by xoxoxoxo on Aug 12, 2015 21:12:37 GMT -5
|
|
|
|
Post by mnholdem on Aug 13, 2015 8:23:25 GMT -5
That reminds me: I intended to post the "non-competing product" section of the MannKind/Sanofi License and Collaboration Agreement. If memory serves, this part of the agreement states that MannKind may not develop any competing drug and that in the event of an acquisition by either MNKD or SNY of a pharmaceutical company that manufactures a competing drug, MNKD/SNY has 12 months to discontinue that competing drug. It makes me wonder if Apidra is about to be discontinued. Because of increasing demands on my time, I haven't had time to really flesh out this section of the agreement. Perhaps others might take a stab at it? www.sec.gov/Archives/edgar/data/899460/000119312514406347/d783199dex101.htmYou'll find what you need at the License and Collaboration Agreement Section 2.8 Covenants (Exhibit 10.1) on page 17, which includes the MannKind and Sanofi Non-Compete language. |
|
|
|
Post by dreamboatcruise on Aug 14, 2015 10:15:22 GMT -5
That reminds me: I intended to post the "non-competing product" section of the MannKind/Sanofi License and Collaboration Agreement. If memory serves, this part of the agreement states that MannKind may not develop any competing drug and that in the event of an acquisition by either MNKD or SNY of a pharmaceutical company that manufactures a competing drug, MNKD/SNY has 12 months to discontinue that competing drug. It makes me wonder if Apidra is about to be discontinued. Because of increasing demands on my time, I haven't had time to really flesh out this section of the agreement. Perhaps others might take a stab at it? www.sec.gov/Archives/edgar/data/899460/000119312514406347/d783199dex101.htmYou'll find what you need at the License and Collaboration Agreement Section 2.8 Covenants (Exhibit 10.1) on page 17, which includes the MannKind and Sanofi Non-Compete language. 1.27 “Competing Product” shall mean any product (other than Product) containing or comprising any formulation of Insulin that is or is intended to be primarily administered in or through the lungs. So Apidra wouldn't have to be discontinued because of this agreement. Even though it's sales are low compared to Novolog and Humalog it probably is enough to be profitable. When I first read the agreement I sort of glossed over this, but just realize that the non-compete would seem to cover inhaled basal if MNKD were to ever consider developing it. I also glossed over the fact that SNY can develop a competing inhaled after 5 years. I thought 5 years would be long enough for Afrezza to be well entrenched, MNKD to have made billions and have other drugs on the market. Now, I'd be a lot more confident if that 5 years was a longer period... given that we're already beyond the one year mark. |
|
|
|
Post by mnholdem on Aug 14, 2015 10:39:17 GMT -5
Glossary/Definition of Terms to the rescue... thanks. Oh, and I do remember reading that if Sanofi does develop its own "competing" drug after five years that Sanofi may not use the Technosphere technology, even though by then they will know how to make the Technosphere particles because of the current agreement, which gives them production rights for Afrezza.
|
|
|
|
Post by dreamboatcruise on Aug 14, 2015 11:04:55 GMT -5
Glossary/Definition of Terms to the rescue... thanks. Oh, and I do remember reading that if Sanofi does develop its own "competing" drug after five years that Sanofi may not use the Technosphere technology, even though by then they will know how to make the Technosphere particles because of the current agreement, which gives them production rights for Afrezza. They are prevented from using any MNKD technology and presumably would have credible Chinese Wall to protect them. The interesting thing is that if I had been MNKD I would have insisted that MNKD's exclusivity end if/when SNY develops competing product. It doesn't appear that is the case. Maybe there is something in other sections that would allow MNKD to get out of the deal if SNY stops marketing Afrezza if/after they develop their own... if they ever do. Counter to my first reaction today... and remembering more of my initial thought process on first reading the agreement... the five year limitation prevents even development work. If they take the internal development path for a competing inhalable, it would be more like 8 to 10 years from now that would be soonest it would be on market. |
|
|
|
Post by bradleysbest on Aug 14, 2015 13:20:17 GMT -5
What happened to the 1000-1500 reps that were supposedly trained about Afrezza in Las Vegas? I thought the SNY Afrezza reps were on commission? If so they are not eating....
|
|
|
|
Post by notamnkdmillionaire on Aug 14, 2015 13:46:31 GMT -5
What happened to the 1000-1500 reps that were supposedly trained about Afrezza in Las Vegas? I thought the SNY Afrezza reps were on commission? If so they are not eating.... it was always speculation that there would be that many reping Afrezza. We now know that isn't the case and never was. |
|
|
|
Post by BlueCat on Aug 14, 2015 19:30:04 GMT -5
Perhaps they were trained to understand it as part of a larger diabetes portfolio, but are not specifically carrying a quota on the product. Much smaller overlay team?
|
|
